Human Treatments
Providing highly effective and affordable treatments for the improvement and maintenance of an individual’s underlying condition and overall quality of life is and will always be our end goal. Immunosyn has been granted by Argyll Biotechnologies, LLC an exclusive, worldwide license to market, sell and distribute the product currently referred to as SF-1019 along with any possible future variants of SF-1019. We anticipated that SF-1019 will be the first of our medicants to receive regulatory approval for human use.
Learn more about SF-1019
Veterinary Treatments
Several members of our Scientific Advisory Board have a great depth of experience in the various fields of veterinary science. So, in addition to marketing, selling and distributing medicants approved for use in humans, Immunosyn intends to take full advantage of its Scientific Advisory Board’s extensive knowledge base by also bringing to the market place biopharmaceuticals products that have been developed for veterinary use. We hope to introduce our first government approved veterinary pharmaceutical in the very near future.
